Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745485 | 1.00 | SETD7 (0.38) | SETD7USP2SMN1; SMN2MAP4K4HSD17B10 | |
| SCHEMBL24267329 | 1.00 | SETD7 (0.38) | SETD7USP2SMN1; SMN2MAP4K4HSD17B10 | |
| SCHEMBL16800202 | 0.85 | CHRM2 (0.37) | SETD7USP2SMN1; SMN2HSD17B10NR1H2 | |
| SCHEMBL13963170 | 0.85 | CHRM2 (0.37) | SETD7USP2SMN1; SMN2HSD17B10NR1H2 | |
| Ethylene SCHEMBL5865026 | 0.84 | SETD7 (0.39) | SETD7USP2SMN1; SMN2MAP4K4HSD17B10 | |
| SCHEMBL30960950 | 0.84 | SETD7 (0.37) | SETD7USP2SMN1; SMN2MAP4K4HSD17B10 | |
| SCHEMBL1197535 | 0.83 | SETD7 (0.40) | SETD7USP2SMN1; SMN2MAP4K4HSD17B10 | |
| SCHEMBL432224 | 0.83 | SETD7 (0.40) | SETD7USP2SMN1; SMN2MAP4K4HSD17B10 | |
| SCHEMBL1197830 | 0.83 | SETD7 (0.40) | SETD7USP2SMN1; SMN2MAP4K4HSD17B10 | |
| SCHEMBL31458016 | 0.83 | CHRM2 (0.39) | USP2SMN1; SMN2HSD17B10NR1H2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| EP-4308562-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-4308559-A1 | BENZISOXAZOLE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-116940571-A | Benzisoxazole derivative and use thereof | 诺华股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| WO-2023184327-A1 | KINASE INHIBITORS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| CN-116802182-A | Pyrazolopyridine derivatives and uses thereof | 诺华股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2022195454-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022195355-A1 | BENZISOXAZOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | SETD7 2946/4885USP2 4303/4885SMN1; SMN2 564/4885 |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | SETD7 2946/4885USP2 4303/4885SMN1; SMN2 564/4885 |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | SETD7 2946/4885USP2 4303/4885SMN1; SMN2 564/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | SETD7 2946/4885USP2 4303/4885SMN1; SMN2 564/4885 |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | HBZ, ZFX, WIZ | SETD7 2621/4885USP2 3987/4885SMN1; SMN2 390/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | SETD7 2946/4885USP2 4303/4885SMN1; SMN2 564/4885 |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | SETD7 2946/4885USP2 4303/4885SMN1; SMN2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.